Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,31€(−92,72%). Der Median liegt bei +1,31€(−92,72%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.» Mehr auf zacks.com
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.» Mehr auf zacks.com
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m.» Mehr auf prnewswire.com

Im letzten Quartal hatte RIGEL PHARMACEUTICALS INC einen Umsatz von 49,30 Mio€ und ein Nettoeinkommen von 10,58 Mio€